#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuromyelitis optica spectrum disorder Albright's disease Lymphatic malformation Fatty acid oxidation disorder Gastric cancer Osteosarcoma Dupuytren's contracture Anal squamous cell carcinoma Urea cycle disorder Arterial disorder Facioscapulohumeral muscular dystrophy Marginal zone lymphoma recurrent Cutaneous lupus erythematosus Juvenile idiopathic arthritis Kidney transplant rejection More trials…

    Learn about Rare Diseases

    Aicardi-Goutieres syndrome – Treatment Antithrombin III deficiency – Life with Disease Fragile X syndrome – Trials in Disease Ewing’s sarcoma metastatic – Life with Disease Kearns-Sayre syndrome – Treatment Osteosarcoma metastatic – Life with Disease Friedreich’s ataxia – Trials in Disease Mucous membrane pemphigoid – Treatment Pleomorphic leiomyosarcoma – Diagnostics Osteosarcoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gfh925 Ttx-030 Metamizole Magnesium Lenograstim Cefixime Sar442970 BNT327 Valganciclovir Hydrochloride Alanine AMO959 ALN-4324 PEGZILARGINASE Liquid Paraffin Amikacin Sulfate Glibenclamide L-Histidine ARGININE GLUTAMATE OSIMERTINIB MESYLATE Desonide Insulin Human (Rdna) More therapies…

    Learn about Your Condition

    Spinal cord injury Rhabdomyosarcoma recurrent Tubulointerstitial nephritis Acute myocardial infarction Thrombotic microangiopathy Peripheral spondyloarthritis Psoriasis Senile dementia Hepatotoxicity Castleman's disease Lymphangioma Hepatic cancer Systemic lupus erythematosus Cardiovascular disorder Haemophilia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Breast cancer

  • Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    • Breast cancer female
    Investigated Drugs:
    • Capivasertib
    • Fulvestrant
    Belgium France Germany Hungary Italy Poland +1

  • Study on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Samuraciclib
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    Belgium France Italy Spain

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6

  • Study on Alpelisib with Fulvestrant or Letrozole for Patients with Advanced Breast Cancer and PIK3CA Mutation After Previous Treatments

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Alpelisib
    • Goserelin
    • Letrozole
    Denmark Italy

  • Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Exemestane
    • Fulvestrant
    Austria Belgium France Germany Greece Italy +2

  • Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Tucatinib
    • Pertuzumab
    • Trastuzumab
    Austria Belgium Czechia Finland France Germany +6
Previous Page
1 … 19 20 21 22 23 … 28
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!